Normal human immunoglobulin 10%

Summary

The procurement is for 10% normal human immunoglobulin, an intravenous medicine used for patients with antibody deficiency or certain autoimmune diseases. It is used for replacement therapy or immunomodulation. Supplies are planned for 24 months under a framework agreement with an estimated total value of EUR 1,285,772.23. The framework agreement will be awarded to one supplier. Tenders must be submitted electronically. Price is the only award criterion, based on the total price including VAT (for a bidder liable for VAT). Bidders must meet the exclusion requirements and be authorised to supply the relevant medicine. Check the tender documents for the detailed qualification and submission requirements.